Chloe Atreya, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Chloe Atreya, MD, PhD

Assistant Clinical Professor, Department of Medicine, UCSF

chloe.atreya@ucsf.edu

Phone: (415) 353-9888
UCSF Box 1705

View on UCSF Profiles

Cancer Center Membership

Associate Member » Developmental Therapeutics

Education

Princeton University,  Princeton NJ, BA, 05/98, Molecular Biology,  Certificate in Visual Art
Yale University,  New Haven,  CT, PhD, 05/04, Pharmacology
Yale University,  New Haven,  CT, MD, 05/05, Medicine
University of Washington,  Seattle,  WA, , 06/08, Internal Medicine,  internship and residency
University of California,  San Francisco, , 06/10, Medical Oncology,  fellowship


Professional Experience

  • University of Michigan Medical Center, Ann Arbor, MI
    06/95-09/95 Research Intern in cardiovascular gene therapy with Dr. Elizabeth Nabel
  • University of Washington Affiliated Hospitals, Seattle, WA
    06/05-06/08 Department of Internal Medicine, Internship and Residency, Categorical Track
  • University of California San Francisco, San Francisco, CA
    07/08-07/10 Department of Medicine, Hematology/ Oncology Fellow
    07/10-07/11 Non-ACGME Postdoctoral Fellow
    07/2011- Adjunct Instructor of Medicine

Honors & Awards

  • University of Michigan Human Genome Center, Ann Arbor, MI
    1993, 92 Howard Hughes Summer Internships with Dr. Francis Collins
  • Princeton University, Princeton, NJ
    1998 Bachelor of Arts, Molecular Biology, High Honors
    1998 Phi Beta Kappa
    1998 Sigma Xi
    1997 Lucas Graphics Prize for the best graphic image by a Princeton student
  • Yale University School of Medicine, New Haven, CT
    2005 MD-PhD Alumni Award
    2005 Janet M. Glasgow Memorial Achievement Citation, presented by the American Medical Women’s Association to women who graduate at the top of their medical school class
  • 2011
    American Cancer Society Postdoctoral Fellowship 11-183-01-TBG
  • 2011
    Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award
  • 2012
    UCSF Resource Allocation Program Spring 2012 Core Exploratory Award
  • 2012
    Alliance for Clinical Trials in Oncology Foundation Investigator Award
  • 2012
    Pilot Research Award for Junior Investigators, Mt. Zion Health Fund, Gump Cancer Fund from the Resource Evaluation and Allocation Committee, and HDFCCC

Selected Publications

  1. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 1; 33(34):4023-31.
    View on PubMed
  2. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  3. Expanded RAS: Refining the Patient Population. J Clin Oncol. 2015 Mar 1; 33(7):682-5.
    View on PubMed
  4. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15; 136(8):1967-75.
    View on PubMed
  5. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.
    View on PubMed
  6. Cancer Medicine. PTEN Expression is Consistent in Colorectal Cancer Primaries and Metastases and Associates with Patient Survival. 2013.
    View on PubMed
  7. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013 Aug; 2(4):496-506.
    View on PubMed
  8. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600.
    View on PubMed
  9. Personalized Medicine in Oncology. KRAS and Colorectal Cancer: Shades of Gray. 2012; 6(1).
    View on PubMed
  10. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9.
    View on PubMed
  11. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25.
    View on PubMed

Go to UCSF Profiles, powered by CTSI